BCG
Binah Capital Group, Inc.·Financial Services
1.76
7.853%(−0.15)
Market ClosedLast Updated: — ET
52W L: $1.3652W H: $3.44
BCG NEWS
defenseworld.net
1d ago
Binah Capital Group (NASDAQ:BCG) Shares Down 9% – Here’s What Happened
Binah Capital Group, Inc. (NASDAQ: BCG - Get Free Report)'s stock price fell 9% during mid-day trading on Thursday. The company traded as low as $1.82 and last traded at $1.91. 144,432 shares traded hands during mid-day trading, a decline of 92% from the average session volume of 1,703,621 shares. The stock had previously closed
globenewswire.com
Mar 31
Binah Capital Group Reports Results for Fourth Quarter and Full Year 2025
– Grew Total Revenue 11% Year-over-Year to $187.1 Million – – Assets Under Management (“AuM”) Increased 11% Year-over-Year to $29.9 Billion – – Net Income of $2.3 Million – – Increased EBITDA [ * ] to $5.4 Million from $2.0 Million in the Prior Year – NEW YORK, March 31, 2026 (GLOBE NEWSWIRE) -- Binah Capital Group, Inc. (“Binah”, “Binah Capital” or the “Company”) (NASDAQ: BCG; BCGWW), a leading financial services enterprise that owns and operates a network of industry-leading firms empowering independent financial advisors, today announced results for the quarter and full year ended December 31, 2025. “We completed our first full year as a public company with strong results in the fourth quarter, which reflects the continuing growth of our differentiated platform,” stated Craig Gould, Chief Executive Officer of Binah Capital Group.
globenewswire.com
Mar 9
Relmada Therapeutics Reports 12-Month Phase 2 Interim Data for NDV-01 in Non-Muscle Invasive Bladder Cancer
Durable 76% complete response (CR) rate at 12 months with 95% CR rate at any time in high-risk NMIBC BCG-unresponsive patients achieved an 80% CR rate at 12 months and 94% CR rate at any time Tolerability profile remains favorable – no ≥ Grade 3 treatment-related adverse events and no treatment-related discontinuations Data reinforces advancement of NDV-01 into Phase 3 RESCUE registrational program in second line (2L) BCG-unresponsive and adjuvant intermediate-risk NMIBC in mid-2026 CORAL GABLES, Fla., March 09, 2026 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada” or the “Company”), a clinical-stage biotechnology company advancing innovative therapies for oncology and central nervous system disorders, today announced 12-month interim data from its ongoing Phase 2 trial evaluating NDV-01 in patients with high-risk non-muscle invasive bladder cancer (NMIBC).
